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AIM: A Belgian registry for pediatric Crohn's disease, BELCRO, was created in which year. 81 
This first report aims at estimating incidence, describing disease presentation and phenotype 82 
and determining associations between variables at diagnosis and registration in the database.  83 
METHODS: Through a collaborative network, children with previously established Crohn’s 84 
disease and newly diagnosed children and adolescents (under 18 y of age) were recruited over 85 
a 2 year period. Data were collected by 23 centers and entered in a database. Statistical 86 
association tests analyzed relationships between variables of interest at diagnosis. 87 
RESULTS: Two hundred fifty-five previously and newly diagnosed patients under 18 y of 88 
age were included. Considering 100 newly diagnosed patients out of 255 included patients, 89 
the approximate estimated incidence was 2.2/105 children <18y/year (CI 1.5-2.8). Median age 90 
at diagnosis was 12.5 y (range: 1.6-18y); median duration of symptoms prior to diagnosis was 91 
3 m (range: 1-12m). Fifty three % of these patients presented with a BMI z-score <-1. 92 
Neonatal history and previous medical history did not influence disease onset nor disease 93 
behavior. CRP was an independent predictor of disease severity. Steroids were widely used as 94 
initial treatment in moderate to severe and extensive disease. Over time, immunomodulators 95 
and biological were prescribed more frequently, reflecting a lower prescription rate for 96 
steroids and 5-ASA. A positive family history was the sole significant determinant for earlier 97 
use of immunosuppression.   98 
CONCLUSION: In Belgium, the median age of children presenting with Crohn‘s disease is 99 
12.5 y. Faltering growth, extensive disease and upper GI involvement are frequent. CRP is an 100 
independent predictive factor of disease activity. A positive family history appears to be the 101 
main determinant for initial treatment choice.   102 
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 106 
Introduction 107 
The incidence of Crohn’s disease (CD) increases especially in Westernized countries 1.  108 
Approximately 25% of patients are affected during childhood 2.  In children, a more severe 109 
and extensive disease phenotype is described compared to adults 3. The impact on the child's 110 
growth and development is an important factor determining treatment strategies. 111 
The natural course of CD remains unpredictable. Based on adult literature, risk factors for 112 
severe disease are younger age at diagnosis, the presence of perianal disease and smoking 4. In 113 
pediatrics, these risk factors need confirmation and other factors, possibly related to growth 114 
and development need to be identified. High concordance of CD in monozygotic twins and a 115 
positive family history for inflammatory bowel disease (IBD) in 5-20% confirms an 116 
underlying genetic susceptibility 5. Environmental influence is proven by the deleterious 117 
effect of smoking and the rise in CD in immigrant populations from regions with low 118 
prevalence to regions with high prevalence 1. Regional information, captured in registries, 119 
aims at providing insights in disease presentation, disease course and influencing 120 
environmental factors 6. We therefore initiated a registry of Belgian pediatric CD patients 121 
(BELCRO). In this manuscript we report on patient characteristics at diagnosis and at 122 
inclusion for previously diagnosed patients.  123 
 124 
MATERIALS AND METHODS 125 
Population 126 
BELCRO was initiated in May 2008 through a collaboration of the IBD working group of the 127 
Belgian Society for Pediatric Gastroenterology, Hepatology and Nutrition (BESPGHAN) and 128 
the Belgian IBD Research and Development Group (BIRD). The aim of the registry is to 129 






and to prospectively follow these patients for 5 y. All Belgian pediatric and adult 131 
gastroenterology centers were invited to participate in the registry. Twenty-three pediatric and 132 
adult units, representing all major Belgian centers and members of the scientific committees 133 
have recruited their patients. The diagnosis of CD had to be established according to the Porto 134 
criteria7. Informed consent was obtained from the parents or legal guardians. The registry was 135 
explained in a comprehensible way to the patients and they gave their assent. The study 136 
protocol was established following the declaration of Helsinki and Good Clinical Practice 137 
guidelines, approved by the ethics committee ZNA Middelheim, Antwerp Belgium (nr 3147) 138 
and registered on clinical trials.gov (B00920083829).  139 
 140 
Data collection 141 
A chart analysis was performed for previously diagnosed CD patients (diagnosed before May 142 
1st 2008). Data at diagnosis and at inclusion in the registry were extracted from the medical 143 
files into a standardized clinical record file (CRF). Data from newly diagnosed patients 144 
(diagnosed after May 1st  2008) were collected in the CRF. All data were entered into an 145 
Excell® database (Microsoft Corporation, Washington, USA) by a dedicated data manager 146 
(DRC Data management, Gent, Belgium). The procedure for data collection and ownership 147 
was described in a Charter by a steering committee comprising the principal investigator and 148 
representatives of the participating scientific societies. 149 
 150 
Description of variables 151 
The following information was collected from all patients at diagnosis: demographics (race, 152 
age, gender), neonatal history (mode of delivery, birth weight, gestational age, mode of 153 
feeding), family history (CD, ulcerative colitis, auto-immune diseases), previous medical 154 
history (infections, surgery, stressful events, food allergies), concomitant conditions 155 






pain, diarrhea, perianal disease, extra-intestinal manifestations), diagnostic work-up 157 
(including laboratory, endoscopy, histology and imaging) and treatment. Upon inclusion in 158 
the database, data on symptoms, vaccinations, therapy, concomitant conditions and laboratory 159 
values were recorded from previously diagnosed patients. Age categories (<6 y, >=6 y-<=12 160 
y, >12 y) were defined to further stratify the population.  161 
Disease severity was scored using the Pediatric Crohn’s Disease Activity Index (PCDAI), a 162 
validated scoring system based on symptoms, biochemical parameters, clinical exam and 163 
growth8. When PCDAI was not available, Physician’s Global Assessment (PGA) was 164 
obtained, based on the clinical evaluation of the patient by his physician. Diagnostic 165 
procedures were recorded and the involved intestinal areas or disease location were derived 166 
from endoscopic data, histology and imaging. Disease location was classified following the 167 
Montreal classification (ileal (L1), colonic (L2) , ileocolonic (L3), upper gastrointestinal (GI) 168 
(L4)) 9 as well as by the more recently published Paris classification 6(L4A upper GI 169 
involvement until the angle of Treitz and L4B upper GI involvement beyond the angle  of 170 
Treitz). Data on initial treatment were collected and stratified in the following categories: 171 
enteral nutrition, rectal therapy, 5 ASA, antibiotics, steroids (budesonide, prednisolone), 172 
immunomodulators (6 mercapotpurine, methotrexate, azathioprine), biologicals (infliximab, 173 
adalumimab), tacrolimus and cyclosporine.  174 
  175 
Statistical analysis 176 
All data were arranged and processed for handling using Microsoft™ Office Excel and 177 
analyzed with SPSS 17.0. Descriptive statistics were used to describe the population 178 
features. Non-parametric association tests were used to investigate relationships between 179 
variables of interest. In particular, Fisher’s exact tests were used to assess relationships 180 
between categorical variables. For continuous variable outcomes and categorical explanatory 181 
variables, Mann-Whitney U tests (Kruskal-Wallis tests when > 2 categories) were performed. 182 






whenever appropriate. All tests were performed on available cases only. Tests were carried 184 
out at a significance level of 5%. To avoid bias, previously diagnosed patients (before May 1st  185 
2008) and newly diagnosed patients (after May 1st  2008) were compared for their differences 186 
and a separate analysis was performed for the differing factors. Logistic regression models 187 




Demographics and neonatal data 192 
Two-hundred fifty-five patients under 18 y at diagnosis (born after May 1st  1990), with 193 
established diagnosis of CD according to the Porto criteria 10 and living in Belgium, were 194 
recruited over a 2 y period (May 1st  2008 - April 30th 2010). In this population 100/255 195 
patients were newly diagnosed and 155/255 were previously diagnosed. The estimated 196 
incidence of pediatric CD in Belgium would be 2.2/105 children <18 y/year (CI 1.5-2.8) based 197 
on the latest Belgian population count < 18 y of age 11, 12. Male/female ratio was 1.2 and 98% 198 
of pediatric patients were Caucasian. The remaining 2% was of Asian or South American 199 
origin. Neonatal data reported a median birth weight of 3.3 kg (range 1.4 - 4.6 kg), a median 200 
gestational age of 40 w (range: 28-42w). Caesarian section occurred in 29 patients (11%) and 201 
78% were exclusively or partially breast fed for a median duration of 7 w (range 0-140w). In 202 
comparing newly diagnosed and previously diagnosed patients no significant difference 203 
appeared for the demographic and neonatal data.  204 
 205 
Previous medical history 206 
Seventy percent of patients were diagnosed by a pediatric gastroenterologist and just more 207 
than half in a university center. In the 3 m before diagnosis, 23% took antibiotics, 23% 208 






% experienced a major stressful event (i.e. defined as being stressful for the patient by the 210 
patient himself, his parents and the physician) and 42% had past surgery, of which ear-nose-211 
throat surgery in 45% and inguinal hernia correction and circumcision in 15%. Disease related 212 
surgery was reported in 17%, consisting of abscess drainages and surgical fistula treatment. 213 
Eight patients had previous appendectomy (7%). In previously and newly diagnosed patients 214 
24% and 7% respectively had disease related surgery prior to diagnosis. With this exception, 215 
no significant differences were found in the medical history of the previously and newly 216 
diagnosed patients.  217 
Immunization data were available from 248 patients. Polio was recorded in 222 patients 218 
(86%). Fifty three patients received vaccines in addition to the national recommendations13, 219 
including hepatitis A, yellow fever, influenza and typhoid.  Six patients were vaccinated for 220 
varicella.  221 
Passive smoking was present in 16% of patients, active smoking in 1%. 222 
Family history 223 
A positive family history for IBD in first degree relatives occurred in 29 patients (11.4%). CD 224 
was mentioned in 25 patients, ulcerative colitis in 4. Both conditions were mutually exclusive. 225 
Auto-immune pathology, including psoriasis, lupus, diabetes type I and celiac disease affected 226 
the broader family (parents, siblings, grandparents, cousins, aunts and uncles) of 35.9% of 227 
patients. Family history was similar in previously and newly diagnosed patients.  228 
Presentation 229 
Belgian pediatric CD patients presented at a median age of 12.5 y (range 1.6 -18.0 y) after a 230 
median duration of symptoms of 3 m (range 1-12 m). Median symptom duration prior to 231 






presented in Figure 1. The main presenting symptoms were abdominal pain (84%), diarrhea 233 
(72%) and weight loss or lack of weight gain (72%).   234 
Of the 208 patients from whom data on height velocity was available, 29% presented with 235 
faltering growth. Height z-scores and BMI z-scores were available from 240 patients. Median 236 
z-score for height was - 0.39 (range – 5.35 to 12.71). Severe growth retardation (z-score < -237 
2SD) affected 8.7% of the population. Median z-score for BMI was -1.04 (range -6.74 to 238 
2.07). Sixty patients (25%) had a BMI z-score <= -2SD. The previously diagnosed group 239 
belonged mostly to the age category >12 y whereas median and mean age were comparable 240 
for previous and recent diagnoses. The previously diagnosed patients had lower z-scores for 241 
height: median -0.52 (range -5.35 to 5.87) compared to a median z-score for height of -0.23 242 
(range -3.40 to 12.71) in newly diagnosed patients. (p=0,016).  243 
 244 
Disease location and severity at diagnosis 245 
Disease location was determined by endoscopy, histology and imaging and classified 246 
according to the Montreal and Paris classification. Results are shown in Table 1. Even though 247 
the diagnosis had to fulfill the Porto criteria, 191/255 patients underwent an upper endoscopy 248 
and the ileum was not evaluated in 12 patients. The upper GI tract was evaluated by imaging 249 
and/or endoscopy in 205/255 patients and was involved in 70%. Isolated ileal disease (L1) 250 
was present in 32 (13%), isolated colonic involvement (L2) in 62 (24%) patients, ileocolonic 251 
disease (L3) in 157 (61 %) and isolated upper GI involvement in 4 patients (2%).  252 
The Paris classification subdivides upper GI involvement in L4A (proximal to Treitz 253 
ligament) and L4B (distal to Treitz ligament). These regions were involved in 144 (56%) and 254 
83 (32%) patients respectively. Fourty eight patients had both L4A and L4B involvement. 255 






was mentioned in 15 patients (5.8%) at diagnosis. Out of the 245 patients in whom extra 257 
intestinal manifestations as defined by the PCDAI were recorded (erythema nodosum, 258 
arthritis, uveitis, arthralgias, pyoderma gangrenosum), 72 scored positive (29%). Disease 259 
severity was measured by PCDAI or PGA. The results are presented in Table 2. Disease was 260 
mild in 24%, moderate in 43% and severe in 28% of the cohort. Disease severity and disease 261 
location were comparable in previously and newly diagnosed patients.  262 
Therapy 263 
Treatment at diagnosis was classified according to the following categories: enteral therapy, 264 
rectal therapy, 5-ASA, antibiotics, steroids (prednisolone, budesonide), immunomodulators 265 
(6MP, methotrexate, azathioprine), biologicals (infliximab, adalumimab), cyclosporine and 266 
tacrolimus. At diagnosis, monotherapy was initiated in 23.9% of patients:  steroids in 10.9% 267 
or 5 ASA in 9%. In the majority of patients, combination therapy was initiated with steroids, 268 
immunomodulators and 5 ASA as main components in respectively 64%, 43% and 40%. In 269 
the previously diagnosed patients, the proportion of patients on 5-ASA as initial treatment 270 
was higher compared to the newly diagnosed patients.  271 
 272 
Previously diagnosed patients at time of inclusion in the database 273 
For the 155/255 previously diagnosed patients the median follow-up at registration in the 274 
database was 2.7 y (range 0.3 - 8.2y) with a median age at registration of 15.9 y (range: 5.3 - 275 
19.8y). The majority of patients had inactive disease (70.4%) and was asymptomatic. Their 276 
median height z-score was -0.47 (range -2.69 to 4.82), their median BMI z-score -0.32 (range 277 
-2.98 to 1.91). Abdominal pain was mentioned in 28.2 %, diarrhoea in 12.4 %, weight loss in 278 
12.5 %, perianal disease in 7.2 % and extra-intestinal manifestations in 10.5%. Twenty 279 






fistulectomies, 6 ileo-caecal resections and 1 small bowel resection, 3 colonic resections and 1 281 
fissure treatment. The majority (84.2%) had received combination treatment including 282 
steroids (65.1%), immunomodulators (65.8%), 5-ASA (48.7%) and/or biologicals (28.9%). At 283 
the date of inclusion in the registry only 18/155 patients received steroids as part of their 284 
therapy (9 budesonide, 9 prednisone). The disease activity was inactive in 8/18 patients, mild 285 
in 7/18 patients and moderate in 3/18.  In 14 other patients start and stop dates of steroid 286 
therapy were imprecise, so they possibly had ongoing treatment. 287 
 288 
Associations at diagnosis (Table 3).  289 
The analysis was carried out on the entire group for variables that did not differ in previously 290 
and newly diagnosed patients. A separate analysis was performed for the differing variables in 291 
order to avoid bias due to group heterogeneity. In the previously diagnosed group, follow-up 292 
data obtained at registration in the database were also analyzed.  293 
Neonatal variables such as birth weight, gestational age and mode of delivery revealed no 294 
associations with age, disease location or disease severity at diagnosis. Breastfed children 295 
were diagnosed at a younger age (p=0.0003) and tended to have more colonic disease (L2) 296 
(p=0.013). No associations were found between medical history (antibiotic use, major 297 
stressful events, surgery and/or infections prior to diagnosis) and disease location or severity 298 
at diagnosis. Younger patients at diagnosis had more infectious episodes before diagnosis 299 
(p=0.015) and received more frequently antibiotics as initial treatment (p= 0.002), as well as 300 
steroids and 5 ASA (p=0.01; p=0.004). Their family history for IBD was more often positive 301 
(p=0.032). Age at diagnosis was not associated with disease location when analyzing the 302 
entire group but in the previously diagnosed, patients presenting with L3 tended to be older 303 
(p=0.057). Height z-scores (p=0.004) and ileocolonic disease location (L3) (p=0.011) were 304 






had less severe disease at diagnosis in univariate analysis. Nevertheless multiple regression 306 
analysis withheld only CRP as independent predictive factor for disease severity.  307 
In the total cohort, several disease related factors influenced the initial treatment choice. 308 
Patients with moderate to severe disease and with L4 involvement were more likely to receive 309 
steroids in combination therapy (p= 0.045 and p=0.048) and enteral therapy in combination 310 
(p=0.005 and p=0.043) as initial management. Initial treatment with immunomodulator 311 
monotherapy was associated with height z-score, disease severity, L1 and L4 location, but the 312 
number of patients on this treatment was extremely limited (4 patients) as were patients on 313 
antibiotic monotherapy (4 patients). Patients with L1 involvement had more often antibiotic 314 
combination therapy (p=0.032). 315 
In newly diagnosed patients, steroids were less likely to be used in patients with perianal 316 
disease (p=0.006) and patients with upper GI involvement (L4A) tended to be older 317 
(p=0.047). Patients with lower z-scores for height were more likely to start enteral nutrition at 318 
diagnosis (p=0.002).   319 
 320 
Associations between variables at diagnosis and at inclusion for previously diagnosed 321 
patients (Table 4).  322 
During the follow up of previously diagnosed patients, we noticed an important effect of the 323 
disease duration on several factors. Patients with a longer disease course at inclusion were 324 
diagnosed at a younger age (<0.001) and had better z-scores for height at diagnosis (p= 325 
0.008). They were more likely to have had 5 ASA at diagnosis (p<0.001). An association was 326 
found between the z-scores for height at diagnosis and BMI z-scores at inclusion (p=0.025) 327 
with weight as interfering factor indicating a better weight gain over time compared to 328 
growth. Patients with concomitant conditions at diagnosis had a better height z-score at 329 






At the time of inclusion, patients with mild disease were more likely to have had steroids at 331 
diagnosis (p=0.004; OR=3.8 (95%CI 1.7-8.4). Patients with L3 had less severe disease at 332 
inclusion (p=0.02; OR 2.8- 95%CI 1.1-7.4), in contrast to patients with L1 who received less 333 
steroids (p=0.03; OR 0.3 -95%CI 0.1-0.9). Need for surgery was only influenced by disease 334 
behavior (S) (p=0.001; OR 6.8 -95% CI 1.8-25.3) not by disease severity, location or other 335 
treatment modalities. No further significant associations were found between disease related 336 
elements such as disease severity or disease location and initial treatment, but a positive 337 
family history for IBD was associated with the use of 5-ASA at diagnosis (OR 2.1 95% CI 338 
1.07-4.49), and 5-ASA and immunomodulators during follow up (p=0.02; OR 2.5- 95%CI 339 
1.1-4.3 and p=0.004; OR 2.7 - 95%CI 1.3-5.5).  340 
There was a decrease in the use of steroids and 5-ASA (p= 0.001; OR 0.02 -95%CI 0.002-0.3; 341 
p=0.001; OR 0.03 -0.004-0.3) and an increase in prescriptions of immunomodulators (p=0.03; 342 
OR 1.8-95%CI 0.08-41.1) over time, paralleling a decrease in disease severity (p=0.01) 343 
(Table 5). The decrease in disease severity can be reflected by the decrease in perianal disease 344 
and extra-intestinal manifestations between diagnosis and inclusion in the database, 345 
respectively 28% vs 7.2% and 29% vs 10.5%. The association between immunomodulator 346 
monotherapy at diagnosis and a better height z-score at inclusion is based on too few patients 347 
(4 patients). 348 
 349 
DISCUSSION  350 
This is the first report on Belgian pediatric CD patients. Nationwide recruitment by pediatric 351 
and adult gastroenterologists, members of national scientific societies BESPGHAN and 352 
BIRD, intended to reach as many pediatric patients as possible. Even though virtually all 353 
pediatric GI centers caring for pediatric IBD patients participated in the study, it is impossible 354 






however improbable that adult gastroenterologist would treat patients below the age of 16 y. 356 
Therefore the incidence or prevalence rate presented here is but an approximation but the best 357 
one possible. A better alternative would be a centralized national registry based on health 358 
insurance data.  359 
Based on BELCRO data, the estimated incidence of CD in Belgian children was 2.2/100 000 360 
children <18y/y. This number compares with previous reports from France and Holland11, 12, 361 
whereas incidence increases to 4.9/100000/y in Sweden 14 and 7/100 000/y  in Finland15. 362 
There is a clear North-South gradient with a higher prevalence in Northern countries 1. The 363 
median age of disease onset in BELCRO patients is comparable to what is found in 364 
surrounding countries 3, 11, 12, 14-19. In contrast to the adult population, the majority of pediatric 365 
patients are male. Female preponderance started to show from age 15 y on. Median duration 366 
of symptoms prior to diagnosis was 3 m, which is shorter than in surrounding countries18. A 367 
possible explanation is that specialized medical care is easily accessible in Belgium, 368 
professional referral is not mandatory, travel distances are short and waiting lists are usually 369 
short or non-existent. Health insurance is offered to all citizens. There are no public 370 
campaigns, thus general awareness of CD is probably comparable to surrounding countries. 371 
The majority of patients were Caucasian, including immigrants from North Africa and Turkey 372 
for whom no subset was made.  373 
Neonatal history and previous medical history did not  neither   influence disease severity nor 374 
disease location in this cohort. Younger age at diagnosis was associated with breastfeeding 375 
and an infectious episode prior to diagnosis. Seventy eight percent of BELCRO patients have 376 
been (partially/exclusively) breastfed in the neonatal period. These results compare to 71% of 377 
mothers starting breastfeeding in the general population 20. The association between 378 
breastfeeding and young age at diagnosis, found in our cohort, differs from the protective 379 






correlation between breastfeeding and L2 remains to be confirmed. The breastfed group was 381 
heterogeneous and recall bias is often a problem in studies recording breastfeeding 22. 382 
Therefore these data should be interpreted with extreme caution. In almost a quarter of 383 
children, an infectious episode was noted in the 3 m before diagnosis of which 40% was 384 
labeled a GI infection. Most of them belonged to the younger age category at diagnosis. This 385 
association is not surprising, as younger children are more prone to infections in general. 386 
Vaccination data indicate good adherence to the vaccination scheme of the American 387 
Academy of Pediatrics also recommended by the Belgian authorities13. Only Polio 388 
vaccination is mandatory. General vaccination coverage is known to be over 80% because all 389 
recommended vaccinations are offered free of charge in special pediatric clinics 13, 23.  For CD 390 
patients additional vaccinations were recently recommended to prevent opportunistic 391 
infections 24-26. Adherence to these recommendations is very low so far. We note that even 392 
though national vaccination coverage is excellent, the information is often not recorded in the 393 
medical files or not transferred when patients make a   transition to adult care. Clearly, more 394 
attention is needed in documenting and updating vaccination status at diagnosis knowing the 395 
risk of opportunistic infections in this patient group due to the immunosuppressive medication 396 
as part of their usual treatment. 397 
Abdominal pain, diarrhea and weight loss were the predominant clinical symptoms as was 398 
reported in literature 16, 18. A BMI z-score below -1 was noticed in half of our pediatric 399 
patients. The importance of growth failure as a presenting feature of CD still needs to be 400 
emphasized. Early treatment and adequate nutrition are crucial for catch up growth and 401 
achieving full height and weight potential. The previously diagnosed group demonstrates 402 
symptom improvement following treatment and a decrease in growth failure. Height z-scores 403 
were inversely correlated to disease severity meaning less severe disease improved growth, 404 






height z-scores at diagnosis, imply in general an even better weight gain compared to growth 406 
catch up. In the newly diagnosed population however, patients with lower z-scores were more 407 
likely to receive enteral nutrition as part of the initial therapy indicating a recent, more 408 
adequate therapeutic strategy for growth retardation at diagnosis. Certain data link growth 409 
impairment to disease location 18, this could not be confirmed in our cohort. The size of the 410 
study population or the limited group of patients with severe growth retardation may influence 411 
this result.  412 
BELCRO confirmed that children with CD present with extensive and severe disease and with 413 
high upper GI tract involvement.  Details on the upper GI tract findings were not available at 414 
this stage and it is possible that they were mainly not specific as involvement was based on 415 
endoscopic and/or radiologic data. While evaluation of disease location for different age 416 
categories, confirmed the finding of predominant colonic disease in the children under 6y of 417 
age 3, 11, 16, 17, it has to be stated that this was a very small group and the difference with ileal 418 
and ileo-colonic disease is small.  419 
The majority of patients had mild to moderate disease at diagnosis as evaluated by PCDAI 420 
and PGA. Even though ileal and ileo-colonic disease seemed to be associated with disease 421 
severity, multiple regression analysis only defined CRP as an independent risk factor for 422 
disease severity. CRP is not part of the PCDAI as a reflection of disease severity but has 423 
proven useful in several studies as a predictive factor for treatment response and to reflect 424 
mucosal healing 27-29.  425 
Family IBD was more often found in young patients, possibly due to an earlier expression of 426 
the disease in the genetically predisposed. Only a positive family history for IBD influenced 427 
initial treatment choice for 5-ASA and rapid introduction of immunomodulators. The high use 428 
of 5 ASA reflects treatment schedules before 2008, when this drug was still frequently used 429 






Our data demonstrates the importance of adequate therapy at diagnosis as more severe initial 431 
treatment results in less severe disease over time. Physicians in this cohort were definitely 432 
compelled to use steroids in combination therapy as initial treatment for more severe disease. 433 
After a mean follow up of 2.7 y for a subgroup, patients who presented with severe disease 434 
were more likely to receive steroids as initial treatment and were also more likely to have 435 
extensive disease (L3), while at inclusion, those patients appeared to be more controlled with 436 
inactive PCDAI scores. The opposite is true for patients with isolated ileal disease. While 437 
65.1% of patients at inclusion had received steroids as part of their previous treatment, only 438 
11.6% were still on this treatment. These findings are markedly better than the American data 439 
where, even though 61% of children showed a response to steroid treatment at 1 y, 31% 440 
developed steroid dependency 31. Another study showed a 40% relapse within 18 months after 441 
discontinuation of this treatment 32. Because of relapse rates, important side effects of steroid 442 
treatment and to improve long term outcome, alternative maintenance therapy and even 443 
induction therapy are investigated such as early immunomodulator use 32, 33, enteral therapy 444 
and in severe cases top down therapy with biologicals34.  Enteral therapy, an effective 445 
treatment in the pediatric CD population, induces remission, improves growth and leads to 446 
mucosal healing35-37. Despite the safety of enteral therapy, our data demonstrate its very 447 
limited use as an initial mono therapeutic approach. The way this treatment is introduced by 448 
the medical team and the support to the patient and the parents determines its success. In the 449 
newly diagnosed patients we notice its increased use for patients with growth retardation. In 450 
this cohort disease location, disease behavior and age at diagnosis did not influence treatment 451 
choice at diagnosis and disease outcome, except for patients with stricturing disease whom 452 
had a greater need for surgery during follow up.  453 
Immunomodulators were frequently prescribed, while biologicals only have a very limited 454 






extreme severe presentation of disease. A significant increase (p<0.001) in biological therapy 456 
and immuunmodulators is noticed over time, reflecting the step up therapy generally used in 457 
pediatrics. Today, except for the use of budesonide in mild to moderate ileal disease and the 458 
use of biologicals in fistulizing disease 38, therapeutic strategy is not influenced by disease 459 
location or behavior even though we notice in our cohort that patients with extensive disease 460 
tend to receive steroids more frequently at diagnosis and biologicals in combination therapy 461 
during follow up. Physicians are less inclined to use biologicals in ileal disease in order to 462 
avoid stricture formation. Recent American data compared the use of biologicals and 463 
immunomodulators within the first 30 days after diagnosis in a diverse group of newly 464 
diagnosed CD patients. No significant outcome differences were noted except that infliximab 465 
treated children tended to be sicker at diagnosis39.  The RISK study group looked 466 
prospectively at the patients with deep ulcerations on colonoscopy at diagnosis. This was 467 
associated with worse clinical parameters at diagnosis and worse disease severity scores 468 
(PCDAI/PGA) at 1 y follow-up, more so for patients who lacked treatment with 469 
immunomodulators or biologicals within 3 months after diagnosis40. These findings indicate 470 
the possible important effect of adequate initial treatment on long term outcome data. 471 
Tailoring treatment becomes the subject of multiple studies; therefore the study of natural 472 
disease history is an important starting point. Further follow up of the BELCRO cohort will 473 
help to confirm or infirm whether step down therapy in severe and extensive cases is 474 
indicated. 475 
BELCRO illustrates the management of pediatric CD in Belgium. Treatment trends change 476 
over time even though clear guidelines on pediatric CD treatment are lacking. Actual 477 
management is based on adult experience and expert opinion.  478 
This first report of Belgian pediatric data confirms that pediatric CD patients present with 479 






influencing onset of disease, disease location and disease severity remains difficult because of 481 
multiple interferences. At diagnosis neonatal parameters or previous medical history do not 482 
influence disease onset and development. The role of breastfeeding needs to be further 483 
defined. High dose corticosteroids at diagnosis seem to determine outcome and disease 484 
behavior over time. This confirms the importance of adequate and sufficient therapy from the 485 
start even though more recently, in pediatrics, we try to avoid long term steroid treatment 486 
because of the known side effects and possible alternatives are being used more often such as 487 
enteral therapy and early immunomodulators. Not disease location, not disease severity, not 488 
age at diagnosis influenced initial treatment choice, only family history played a role in this 489 
cohort. The initial follow up data illustrates an evolving therapeutic strategy. Follow-up of 490 
this cohort will provide a better insight in the impact of therapeutic strategy on disease course 491 
by comparing previously and newly diagnosed patients. Presenting features should help 492 
determine individualized therapeutic regimens in the future.  493 
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